Julia Aijun Wang
Known title: Chief Financial OfficerCIK: 0001860279
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
Transaction History
| LH | ▲ Buy | Option Exercise | 860 | — | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 245 | $71K | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 254 | $70K | 2/6/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 893 | — | 2/6/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 336 | $83K | 2/6/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 893 | — | 2/6/2025 | View on chart |
| ONC | ▼ Sell | Open Market | 472 | $68K | 7/1/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 899 | $140K | 6/24/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 195 | $31K | 6/17/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 154 | $24K | 6/17/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 253 | $40K | 6/17/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 314 | $50K | 6/17/2024 | View on chart |
| ONC | ▲ Buy | Grant | 136,240 | $0 | 6/5/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 397 | $66K | 2/29/2024 | View on chart |
| ONC | ▼ Sell | Open Market | 472 | $85K | 7/3/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 840 | $154K | 6/23/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 190 | $37K | 6/20/2023 | View on chart |
| ONC | ▲ Buy | Grant | 107,770 | $0 | 6/15/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 343 | $82K | 3/1/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 295 | $47K | 7/1/2022 | View on chart |
| ONC | ▲ Buy | Grant | 104,377 | $0 | 6/22/2022 | View on chart |
| ONC | ▼ Sell | Open Market | 161 | $22K | 6/17/2022 | View on chart |
| ONC | ▲ Buy | Grant | 61,750 | $0 | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.